# Judith Bellmann–Strobl

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/judith-bellmann-strobl/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,136 |
| Field | Multiple Sclerosis Research Studies |
| h-index | 50 |
| i10-index | 141 |
| Last Known Institution | Max Delbrück Center |
| OpenAlex ID | https://openalex.org/A5051945240 |
| ORCID iD | 0000-0003-2615-1643 |
| Works | 239 |

## Researcher papers

- [A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity](https://scholariq.org/papers/a-prospective-observational-study-of-post-covid-19-chronic-fatigue-syndrome/)
- [Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS)](https://scholariq.org/papers/endothelial-dysfunction-and-altered-endothelial-biomarkers-in-patients-with-post/)
- [MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome](https://scholariq.org/papers/mog-igg-in-nmo-and-related-disorders-a-multicenter-study-of-50-patients-part-3/)
- [MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients](https://scholariq.org/papers/mog-igg-in-nmo-and-related-disorders-a-multicenter-study-of-50-patients-part-4/)
- [Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management](https://scholariq.org/papers/update-on-the-diagnosis-and-treatment-of-neuromyelitis-optica-spectrum-disorders/)
- [Apheresis therapies for NMOSD attacks](https://scholariq.org/papers/apheresis-therapies-for-nmosd-attacks/)
- [Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis](https://scholariq.org/papers/update-on-the-diagnosis-and-treatment-of-neuromyelits-optica-spectrum-disorders/)
- [TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis](https://scholariq.org/papers/tnf-related-apoptosis-inducing-ligand-trail-as-a-potential-response-marker-for/)
- [Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study](https://scholariq.org/papers/fatigue-in-multiple-sclerosis-is-closely-related-to-sleep-disorders-a/)
- [Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome](https://scholariq.org/papers/retinal-ganglion-cell-and-inner-plexiform-layer-thinning-in-clinically-isolated/)
- [Fasting, ketogenic, and anti-inflammatory diets in multiple sclerosis: a randomized controlled trial with 18-month follow-up](https://scholariq.org/papers/fasting-ketogenic-and-anti-inflammatory-diets-in-multiple-sclerosis-a-randomized/)

## Researcher topics

- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Peripheral Neuropathies and Disorders](https://scholariq.org/topics/peripheral-neuropathies-and-disorders/)
- [Long-Term Effects of COVID-19](https://scholariq.org/topics/long-term-effects-of-covid-19/)
- [Fibromyalgia and Chronic Fatigue Syndrome Research](https://scholariq.org/topics/fibromyalgia-and-chronic-fatigue-syndrome-research/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)

## Researcher university

- [Max Delbrück Center](https://scholariq.org/institutions/max-delbruck-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.